EPA Public Access

Author manuscript

Metabolomics. Author manuscript; available in PMC 2020 January 03.

About author manuscripts

Submit a manuscript

Published in final edited form as:

Metabolomics. ; 15(1): 4. doi:10.1007/s11306-018-1460-7.

Towards Quality Assurance and Quality Control in Untargeted Metabolomics Studies

Richard D. Beger¹, Warwick B. Dunn², Abbas Bandukwala³, Bianca Bethan⁴, David Broadhurst⁵, Clary B. Clish⁶, Surendra Dasari⁷, Leslie Derr⁸, Annie Evans⁹, Steve Fischer¹⁰, Thomas Flynn³, Thomas Hartung¹¹, David Herrington¹², Richard Higashi¹³, Ping-Ching Hsu¹⁴, Christina Jones¹⁵, Maureen Kachman¹⁶, Helen Karuso¹⁷, Gary Kruppa¹⁸, Katrice Lippa¹⁵, Padma Maruvada¹⁹, Jonathan Mosley²⁰, Ioanna Ntai²¹, Claire O'Donovan²², Mary Playdon²³, Daniel Raftery²⁴, Daniel Shaughnessy²⁵, Amanda Souza²¹, Timothy Spaeder⁹, Barbara Spalholz²³, Fariba Tayyari²⁶, Baljit Ubhi²⁷, Mukesh Verma²³, Tilman Walk⁴, Ian Wilson²⁸, Keren Witkin²³, Daniel W. Bearden²⁹, and Krista A. Zanetti²³

¹National Center for Toxicological Research, US Food and Drug Administration, Jefferson, USA

²School of Biosciences, Phenome Centre Birmingham and Institute for Metabolism and Systems Research, University of Birmingham, Birmingham, B15 2TT, UK

³Food and Drug Administration, Silver Spring, MD, USA

⁴Metanomics Health GmbH, Berlin, Germany

⁵Edith Cowan University, Perth, AU

⁶Broad Institute of MIT and Harvard, Cambridge, MA, USA

⁷Mayo Clinic, Rochester, MN, USA

⁸National Institutes of Health, Bethesda, MD, USA

⁹Metabolon, Research Triangle Park, NC, USA

¹⁰Agilent Technologies, Santa Clara, CA, USA

¹¹Johns Hopkins School of Public Health, Baltimore, MD, USA

¹²Wake Forest University, Winston-Salem, NC, USA

¹³University of Kentucky, Lexington, KY, USA

Author contributions

All authors contributed equally to the preparation of this manuscript.

Notes

Conflict of interest

There are no conflicts of interest to disclose. The authors declare no competing financial interests. The views presented here do not necessarily reflect those of the U.S. Food and Drug Administration. Views expressed in this article are those of the authors and do not necessarily represent views or policies of the US EPA. Mention of products or trade names does not indicate endorsement of by the US EPA. Any use of trade, firm, or product names is for descriptive purposes only and does not imply endorsement by the U.S. Government.

Research involving human and animal participants

No research involving human or animal participants is included.

Informed consent

No research involving human participants is included and no informed consent was therefore collected.

- ¹⁴University of Arkansas Medical Sciences, Little Rock, AR, USA
- ¹⁵National Institute of Standards and Technology, Gaithersburg, MD, USA
- ¹⁶University of Michigan, Ann Arbor, MI, USA
- ¹⁷Biocrates Inc., Innsbruck, AT
- ¹⁸Bruker Daltronics, Billerica, MA, USA
- ¹⁹National Institute of Diabetes and Digestive and Kidney Disorders, Bethesda, MD, USA
- ²⁰National Exposure Research Laboratory, US Environmental Protection Agency, Athens, GA, USA
- ²¹Thermo Fisher Scientific, San Jose, CA, USA
- ²²European Molecular Biology Laboratory - European Bioinformatics Institute, Hinxton, UK
- ²³National Cancer Institute, Rockville, MD, USA
- ²⁴University of Washington, Seattle WA, USA
- ²⁵National Institute of Environmental Health, Durham, NC, USA
- ²⁶University of Georgia, Athens, GA, USA
- ²⁷AB Sciex, Framingham, MA, USA
- ²⁸Imperial College London, London, UK
- ²⁹National Institute of Standards and Technology, Charleston, SC, USA

Abstract

We describe here the agreed upon first development steps and priority objectives of a community engagement effort to address current challenges in quality assurance (QA) and quality control (QC) in untargeted metabolomic studies. This has included (1) a QA and QC questionnaire responded to by the metabolomics community in 2015 which recommended education of the metabolomics community, development of appropriate standard reference materials and providing incentives for laboratories to apply QA and QC; (2) a 2-day ‘Think Tank on Quality Assurance and Quality Control for Untargeted Metabolomic Studies’ held at the National Cancer Institute’s Shady Grove Campus and (3) establishment of the Metabolomics Quality Assurance and Quality Control Consortium (mQACC) to drive forward developments in a coordinated manner.

Graphical Abstract

Keywords

Quality assurance (QA); Quality control (QC); Community engagement; Test materials; Reporting metrics

1 Introduction

Metabolites have many important biological roles [for example, (Drenos et al. 2016; Kaddurah-Daouk and Weinshilboum 2015)] and the study of metabolites by advanced analytical and informatic platforms is defined as metabolomics. There are numerous sub-specialties in the field of metabolomics; for example, metabolomics investigations of drug response are often referred to as ‘pharmacometabolomics’. Two general types of approaches can be applied depending on the study objectives, either discovery-based (untargeted) studies which have the objective to investigate hundreds or thousands of known and unknown metabolites to generate targets for further investigation, or targeted metabolomic studies which are focused on the investigation of a small subset of metabolites of known biological relevance though assays and studies can integrate untargeted and targeted studies, for example see (Davies et al. 2014). QA and QC processes are hugely important to ensure that the data acquired and reported in scientific publications and housed in data repositories are of high quality and are analytically reproducible. These processes relate to the procedures applied in preparation for data acquisition (QA) and during/after data acquisition (QC) [for example, (ISO 9000 2015)]. QA processes include staff training, standard operating procedures, instrument maintenance and calibration, as well as other processes. QC processes include use of measured data from standard/certified reference materials and quality control samples to address the veracity of experimental data as well as other processes. For targeted studies, there is a long history of defined criteria for QA and QC processes, reporting of data quality for biological samples and standard reference materials and for assessment and reporting of data quality [for example, (FDA 2001)]. However, these criteria and biological samples are not routinely applied, are not available, or otherwise inappropriate for untargeted studies but are urgently required to enable the quality of these studies to be peer reviewed and accepted in the scientific community (Bouhifd et al. 2015). Without well-defined QA and QC procedures for untargeted metabolomics, harmonization across laboratories and multi-laboratory studies become nearly impossible. A recent example from the lipidomics research community has demonstrated how standard reference materials can be applied for community harmonization including QA and QC (Bowden et al. 2017).

A QA and QC questionnaire responded to by the metabolomics community in 2015 provided four key recommendations as shown in Table 1 (Dunn et al. 2017).

2 Think Tank on quality assurance and quality control for untargeted metabolomic studies

Following up on these recommendations, a two-day ‘Think Tank on Quality Assurance and Quality Control for Untargeted Metabolomic Studies’ was held on October 19–20, 2017 at

the National Cancer Institute's Shady Grove Campus in Rockville, MD, USA. The four organizers were Drs. Richard Beger (Food and Drug Administration, USA), Dan Bearden (National Institute of Standards and Technology, USA), Warwick Dunn (University of Birmingham, UK) and Krista Zanetti (National Cancer Institute, USA). Fifty internationally recognized experts in metabolomics and QA/QC processes were invited from the United States, Europe, and Australia with scientists and stakeholders from instrument manufacturers, commercial laboratories, and government and academic institutions invited. 38 of the invited experts attended including NIH Program Staff. The application area focus was on human and biomedical investigations with a goal to communicate and integrate with other application areas (e.g. in toxicology with the "MEtabolomics standaRds Initiative in Toxicology (MERIT)" funded consortium). The objectives of the Think Tank were to:

1. Identify and prioritize the types of test materials that are needed in the field of metabolomics for QA/QC in untargeted studies
2. Identify the most useful metrics for assessing study and data quality for untargeted metabolomic studies
3. Identify and prioritize processes to ensure appropriate reporting of QA/QC data.

The Think Tank had presentations from leading experts to initiate discussions, followed by facilitated breakout sessions where small groups of attendees answered six different questions. Each attendee had the opportunity to provide input for each of the questions posed. Following the breakout sessions, the information gathered was collated and reported to the larger group. The information was then prioritized through an open voting process that allowed for each attendee to weigh in equally with other attendees. The questions posed and priorities identified are outlined in Table 2.

Following the breakout groups, the attendees identified the overall priorities to address current gaps in the use of QA and QC processes in untargeted metabolomics. The consensus was that there is merit in starting with a set of simple priorities and then increasing their complexity. The consensus priorities are listed below:

1. Publish a workshop report to communicate the meeting proceedings to the metabolomics community and allow new members to join the consortium.
2. Publish a white paper which could include: (1) metabolomics practices with a focus on QA/QC procedures; (2) an emphasis on the use of QC samples as best practices and give examples of current use; (3) a discussion of metabolomics QA/QC being a developing principle, the need to develop standards, and the need for the wider community to be involved in the process; and (4) a description of the QC procedures performed in experienced labs to begin a community dialogue on the topic.
3. Engage scientific journals to report that the community believes that good, documented QC practices, including analysis of QC samples, should be part of the acceptance criteria for publication.
4. Document and subsequently publish the complete experimental procedure for metabolomics, including the QC practices

5. Establish a community forum to discuss the development of reference standards, and interlaboratory comparison exercises.
6. Engage the community to identify key reference materials that need to be developed.
7. Form a steering committee and larger scientific advisory board.
8. Identify funding opportunities to hold meetings and continue the group discussion and planning.
9. Organize workshop(s) on QA/QC at the Metabolomics Society meeting to promote community engagement in these efforts.

3 Establishment of the Metabolomics Quality Assurance and Quality Control Consortium (mQACC)

Following the inaugural meeting, the group has continued to be active, and ultimately established the Metabolomics Quality Assurance and Quality Control Consortium (mQACC). The establishment of the consortium will provide a structure for the Think Tank participants to not only continue these efforts, but expand them to include the broader metabolomics community. The consortium logo is shown below and further information is available at <https://epi.grants.cancer.gov/Consortia/mQACC/>

References

- Bouhifd M, Beger R, Flynn T, Guo L, Harris G, Hogberg H, Kaddurah-Daouk R, Kamp H, Kleensang A, Maertens A, & Odwin-DaCosta S (2015). t4 Workshop Report: Quality Assurance of Metabolomics. *Altex*, 32(4), 319. [PubMed: 26536290]
- Bowden JA, Heckert A, Ulmer CZ, Jones CM, Koelmel JP, Abdullah L, et al. (2017). Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using standard reference material 1950 metabolites in frozen human plasma. *Journal of Lipid Research*, 58(12), 2275–2288. [PubMed: 28986437]
- Davies SK, Ang JE, Revell VL, Holmes B, Mann A, Robertson FP, et al. (2014). Effect of sleep deprivation on the human metabolome. *Proceedings of the National Academy of Sciences*, 111(29), 10761–10766.
- Drenos F, Davey Smith G, Ala-Korpela M, Kettunen J, Würtz P, Soininen P, et al. (2016). Metabolic characterization of a rare genetic variation within APOC3 and its lipoprotein lipase-independent effects. *Circulation: Genomic and Precision Medicine*, 9(3), 231–239.
- Dunn WB, Broadhurst DI, Edison A, Guillou C, Viant MR, Bearden DW, et al. (2017). Quality assurance and quality control processes: summary of a metabolomics community questionnaire. *Metabolomics*, 13(5), 50.
- Food and Drug Administration (FDA). (2001) Guidance for industry: Bioanalytical method validation Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research
- ISO 9000. (2015). Quality management systems—Fundamentals and vocabulary, Geneva: ISO.
- Kaddurah-Daouk R, & Weinshilboum R (2015). Metabolomic signatures for drug response phenotypes: Pharmacometabolomics enables precision medicine. *Clinical Pharmacology & Therapeutics*, 98(1), 71–75. [PubMed: 25871646]

Table 1.

Four recommendations as defined from a 2015 questionnaire responded to by the metabolomics community [6] and which were used to develop the agenda for the Think Tank on Quality Assurance and Quality Control in Untargeted Metabolomics Studies

Recommendation
<i>Appropriate agencies and the Metabolomics Society should provide guidance on quality assurance processes and their review and develop consensus processes through specialist meetings and reports</i>
<i>To provide education to the metabolomics community; with an emphasis on early career scientists, on usage of quality materials, and to provide continuing education to ensure these good practices continue</i>
<i>To communicate with the metabolomics community to define the types and volumes of Standard Reference Materials required</i>
<i>Recognizing the need to provide further incentive for laboratories to improve overall QA/QC practices, expert panels should be convened to develop workable, practical QA/QC recommendations and guidelines.</i>

Table 2.

Breakout session questions and recommended actions identified at the Think Tank on Quality Assurance and Quality Control in Untargeted Metabolomics Studies.

Question	Recommended actions
What are the current gaps that should be addressed to establish widespread best practices for QA in untargeted metabolomics?	<ul style="list-style-type: none"> * Document complete experimental processes and reporting from study design to data analysis * Focus is not just analytical but study protocols * Training and education, different for researchers and users new to the scientific discipline versus experienced researchers in the discipline * Define the best practices and those that should be avoided in sample collection, processing and storage
What are the current gaps that should be addressed to establish widespread best practices for QC protocols in untargeted metabolomics?	<ul style="list-style-type: none"> * Obtain buy in from scientific journals, companies, software developers, database developers, and funders * Define best QC practices * Need agreement and to encourage/enforce QC practices * Educate community about QC procedures
What is needed to establish QC acceptance criteria reporting across the wider community?	<ul style="list-style-type: none"> * Establish minimum acceptance criteria, including creating a broad-based scoring system [For example, one QC scoring scheme could include: (i.e. 0=none, 1=pooled, 2=pooled and SRM)] * Create reporting standards/SOPs for the entire analytical process
What should be the minimum QA and QC reporting standards for publications and databases?	<ul style="list-style-type: none"> * Define acceptance criteria [e.g. scoring system (or explain why criteria were not met)] * QC metadata should be reported (e.g. sample order, QC sample reference material used) and define elements under each category with adequate details for reproducibility
What are the key characteristics of high-availability test material sample types for metabolomics?	<ul style="list-style-type: none"> * Develop test materials for inter-laboratory comparisons * Quantitative/semi-quantitative comparisons * Inexpensive materials * Same sample for all technologies – must cover wide range of characteristics * Develop key data quality metrics for each platform and test material.
What best use practices should be established for test material samples by the community?	<ul style="list-style-type: none"> * Define best practices * Need consensus, including when you run the test material and timing of use, to allow for data harmonization * Context dependent (i.e., highly dependent on matrix) * Determine if test materials should be accompanied by SOPs * Test materials should be used in conjunction with other QC samples * Use for lab qualification, instrument qualification, training